Gliclize MV 0.2 – Gliclazide IP 80 Mg + Metformin Hcl IP 500 Mg + Voglibose IP 0.2 Mg
Gliclazide IP 80 Mg + Metformin Hcl IP 500 Mg + Voglibose IP 0.2 Mg
Exporter, Distributor Drop shipper to Russia, Brazil, Colombia, Latin America And East Asia
Gliclize MV 0.2 contains Gliclazide IP 80 mg, Metformin Hydrochloride IP 500 mg, and Voglibose IP 0.2 mg, a triple-action antidiabetic formulation indicated for the management of Type 2 Diabetes Mellitus. It helps improve glycemic control by stimulating insulin secretion, reducing hepatic glucose production, improving insulin sensitivity, and delaying carbohydrate absorption to effectively control both fasting and postprandial blood glucose levels.
|
Contain |
Gliclazide IP 80 Mg + Metformin Hcl IP 500 Mg + Voglibose IP 0.2 Mg |
|---|---|
|
Strength |
80 Mg + 500 Mg + 0.2 Mg |
|
Packaging |
10X10TAB |
|
Category |
Categories: Diabetic Care |
|
Manufacturer |
Johnlee Pharmaceuticals Pvt. Ltd |
|
Brand |
Gliclize |
Product Overview
Gliclize MV 0.2 is a triple-combination oral antidiabetic medication containing Gliclazide IP 80 mg, Metformin Hydrochloride IP 500 mg, and Voglibose IP 0.2 mg. It is specifically formulated for the effective management of Type 2 Diabetes Mellitus in patients who require comprehensive glycemic control beyond monotherapy or dual therapy. By combining three complementary mechanisms of action, Gliclize MV 0.2 helps achieve better control of both fasting and post-meal blood glucose levels.
Gliclazide stimulates insulin secretion from the pancreatic beta cells, Metformin reduces hepatic glucose production and improves insulin sensitivity, while Voglibose delays the digestion and absorption of carbohydrates in the intestine, thereby minimizing postprandial blood glucose spikes. Together, these actions provide comprehensive blood glucose management and support long-term metabolic control.
Gliclize MV 0.2 is commonly prescribed alongside dietary modifications, regular physical activity, and lifestyle management. The combination therapy helps simplify treatment by reducing pill burden while improving patient adherence and supporting long-term diabetes management.
Manufactured under stringent pharmaceutical quality standards, Gliclize MV 0.2 delivers consistent efficacy, safety, and reliability, making it a trusted therapeutic option for modern diabetes care.
How It Works
Gliclazide stimulates insulin release from pancreatic beta cells, helping lower blood glucose levels. Metformin decreases glucose production by the liver, improves insulin sensitivity, and reduces intestinal glucose absorption. Voglibose inhibits intestinal alpha-glucosidase enzymes, slowing carbohydrate digestion and reducing the rise in blood glucose after meals. Together, these complementary mechanisms provide comprehensive glycemic control throughout the day.
Therapeutic Applications
Gliclize MV 0.2 may be prescribed for the management of:
- Type 2 Diabetes Mellitus
- Inadequately Controlled Blood Glucose Levels
- Postprandial Hyperglycemia
- Long-Term Glycemic Management
- Combination Antidiabetic Therapy
- Patients requiring triple-mechanism glucose control
Key Benefits
- Triple-action therapy for comprehensive blood glucose management.
- Helps control both fasting and postprandial blood glucose levels.
- Improves insulin secretion and insulin sensitivity.
- Delays carbohydrate absorption to reduce post-meal glucose spikes.
- Convenient combination therapy to improve treatment adherence.
- Manufactured under stringent pharmaceutical quality standards.
Quality Commitment
Vinix Biopharma is committed to delivering high-quality antidiabetic medicines manufactured in accordance with stringent pharmaceutical quality standards. Gliclize MV 0.2 undergoes comprehensive quality assurance and rigorous quality testing to ensure safety, efficacy, consistency, and reliability. Every batch is carefully evaluated to maintain product integrity and support optimal patient care.
Storage Information
Store in a cool, dry place below 30°C. Protect from moisture and direct sunlight. Keep out of reach of children.
Disclaimer
Gliclize MV 0.2 should be used only under the supervision of a qualified healthcare professional. Dosage and duration of treatment should be determined by the treating physician based on the patient’s clinical condition, medical history, and therapeutic requirements.
